Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has closed a previously announced private placement, raising approximately $3.448 million through convertible promissory notes. The notes, priced at-the-market under Nasdaq rules, have a 3-month maturity and 6% annual interest rate, with immediate conversion options into common stock.

The private placement included participation from company executives, including CEO Lisa Conte, board members, and selected institutional and accredited investors. The deal also included unregistered warrants exercisable immediately with a five-year expiration term. H.C. Wainwright & Co. served as the exclusive placement agent.

The company plans to use the net proceeds for working capital and general corporate purposes, particularly focusing on upcoming Q2 2025 catalysts related to crofelemer development for rare diseases and cancer therapy-related diarrhea.

Positive

• Management participation in the financing demonstrates insider confidence
• Immediate funding secured for Q2 2025 development initiatives
• At-the-market pricing aligns with current market valuation

Negative

• Short-term 3-month maturity creates near-term refinancing pressure
• Potential dilution from convertible notes and warrants
• Additional debt burden with 6% interest rate

Insights

Financial Analyst

Jaguar Health's $3.448 million bridge financing raises significant concerns about the company's financial position. This financing nearly equals the company's entire $3.5 million market capitalization, suggesting severe capital constraints. The 3-month maturity term is unusually short for biotech financing, creating imminent refinancing pressure by July 2025.

The structure of this deal - convertible notes with immediate conversion rights plus warrants - will likely result in substantial dilution for existing shareholders. While management participation signals some internal confidence, the financing terms suggest unfavorable conditions:

• The 6% interest rate on a very short-term note
• At-market pricing (no discount) despite the company's precarious financial position
• Requirement for the full conversion rights to be immediately available
• Inclusion of warrants further increasing potential dilution

This appears to be emergency bridge funding designed to keep operations running through Q2 catalysts. H.C. Wainwright's involvement as placement agent provides some credibility, but investors should recognize this financing as a high-risk stopgap measure rather than a sustainable capital solution. The extremely short maturity creates a narrow window for Jaguar to demonstrate value through its upcoming catalysts before facing another potential capital crisis.

Biotech Development Specialist

This bridge financing reveals a critical strategy by Jaguar to secure operational runway through Q2 2025, when they anticipate key value-inflection points for their lead compound crofelemer. The company is pursuing dual development paths:

• Rare disease applications (likely targeting orphan drug designations)
• Cancer therapy-related diarrhea (CTRD) - an underserved but significant market opportunity

The timing is telling - management believes that within the next three months, developmental milestones could substantially enhance company value. For a small-cap biotech with resources, this concentrated catalyst period represents both opportunity and risk.

Crofelemer is not a new compound but rather a plant-derived drug with established safety data, which reduces some development risk. However, the extreme urgency implied by this short-term financing suggests these upcoming Q2 events are binary outcomes that could determine the company's future. Management's willingness to personally invest alongside this bridge round indicates confidence, but also demonstrates they couldn't secure more favorable terms despite insider participation.

The focus on rare diseases and CTRD represents a strategic pivot toward higher-value, potentially expedited regulatory pathways, but the compressed financing timeline leaves minimal margin for developmental delays or setbacks. For a $3.5M market cap company, this represents an all-or-nothing gambit on near-term clinical progress.

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.

Jaguar's president and chief executive officer Lisa Conte, as well as other members of the Company's board of directors and other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements in connection with this private placement, pursuant to which the Company issued approximately $3.448 million aggregate principal amount of convertible promissory notes (collectively, the "Notes") to such Investors in a private placement priced at-the-market under Nasdaq rules. The Notes have a 3-month maturity, bear interest at 6% per annum, and will be convertible immediately at the option of the Investors into shares of the Company's common stock.

In addition, the Company issued to the Investors unregistered warrants, which are exercisable immediately and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.

"As announced, a number of key catalysts are expected to occur in the second quarter of 2025 - primarily associated with ongoing crofelemer development efforts for rare diseases and cancer therapy-related diarrhea - that the Company believes have the potential to be value-enhancing for the Company. We feel it is important that Jaguar is adequately funded during this key time period," said Conte.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds to Jaguar from the offering were approximately $3.448 million, before deducting the placement agent's fees and other offering expenses payable by Jaguar, and excluding the proceeds, if any, from the exercise of the warrants. Jaguar intends to use the net proceeds from the offering for working capital and other general corporate purposes.

The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the convertible notes and the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities described above, including the shares of common stock underlying the convertible notes and the warrants, may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the registration rights agreements with investors, the Company has agreed to file a resale registration statement covering the resale of the shares of common stock underlying the convertible notes and warrants.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the intended use of proceeds from the offering,Jaguar's expectation that a number of key catalysts may occur in the second quarter of 2025 - primarily associated with ongoing crofelemer development efforts for rare diseases and cancer therapy-related diarrhea, and Jaguar's expectation that these catalysts may have the potential to be value-enhancing for the Company.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the size and terms of Jaguar Health's (JAGX) April 2025 bridge financing?

Jaguar Health raised $3.448 million through convertible notes with 3-month maturity and 6% annual interest rate, including warrants with 5-year expiration.

How will JAGX use the proceeds from the April 2025 private placement?

The proceeds will be used for working capital and general corporate purposes, supporting crofelemer development initiatives in Q2 2025.

Who participated in JAGX's April 2025 private placement?

CEO Lisa Conte, board members, C-suite executives, and selected institutional and accredited investors participated in the placement.

What are the key catalysts expected for JAGX in Q2 2025?

Key catalysts relate to ongoing crofelemer development for rare diseases and cancer therapy-related diarrhea treatments.